NASDAQ : SCTX
Scribe Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 17.44 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 330.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 291.93M |
| Enterprise Value | 292.19M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 18.93M |
| Shares Outstanding | 18.93M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.61% |
| Owned by Insiders (%) | 8.80% |
| Owned by Institutions (%) | 14.31% |
| Float | 6.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.77 |
| Forward PS | 26.75 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 8.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.57 |
| Quick Ratio | 0.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.83 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 147.84% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $406,122 |
| Profits Per Employee | -$393,951 |
| Employee Count | 82 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -334,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 24.10 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 36.53 |
| Average Volume (20 Days) | 438,288 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.12M |
| Short Previous Month | 2.47M |
| Short % of Shares Out | 5.91% |
| Short % of Float | 16.24% |
| Short Ratio (days to cover) | 1.96 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 33.30M |
| Gross Profit | -17.75M |
| Operating Income | -30.71M |
| Pretax Income | -32.64M |
| Net Income | -32.30M |
| EBITDA | -27.82M |
| EBIT | -30.71M |
| Loss Per Share | -$13.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 43.01M |
| Total Debt | 43.27M |
| Net Cash | -261,000 |
| Net Cash Per Share | -$0.01 |
| Equity (Book Value) | -44.49M |
| Book Value Per Share | -66.33 |
| Working Capital | -33.59M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -37.85M |
| Capital Expenditures | -368,000 |
| Depreciation & Amortization | 2.89M |
| Net Borrowing | n/a |
| Free Cash Flow | -38.22M |
| FCF Per Share | -$2.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | -53.29% |
| Operating Margin | -92.20% |
| Pretax Margin | -98.01% |
| Profit Margin | -97.00% |
| EBITDA Margin | -83.54% |
| EBIT Margin | -92.20% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -85.45% |
| FCF Yield | -13.09% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $57.00 |
| Price Target Difference | 269.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | -48.48% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.26 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |